Iteos Therapeutics, INC

iTeos Therapeutics, Inc. completes merger with Concentra Biosciences, LLC, offering shareholders $10.047 cash plus a contingent value right per share.

iTeos Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 per share in cash plus a contingent value right, following a unanimous board recommendation.

iTeos Therapeutics, Inc. announced that its stockholders re-elected all Class II director nominees and ratified the appointment of Deloitte Bedrijfsrevisoren / Rviseurs dEntreprises BV/SRL as its independent registered public accounting firm at the Annual Meeting held on June 17, 2025.

iTeos Therapeutics, Inc. announced the immediate resignation of Tim Van Hauwermeiren from its Board of Directors, effective June 1, 2025.

iTeos Therapeutics, Inc. announced its intention to wind down clinical and operational activities, including the termination of its belrestotug program and GSK collaboration, to maximize shareholder value through leveraging its cash balance and potential asset sales.

iTeos Therapeutics and GSK halt the development of belrestotug following unfavorable interim results from the GALAXIES Lung-201 study, prompting iTeos to initiate a strategic review to maximize shareholder value.

iTeos Therapeutics reports significant losses and plans to wind down operations, entering a merger agreement with Concentra Biosciences for $10.047 cash plus a contingent value right per share.

iTeos Therapeutics announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and providing an update on its financial position.

iTeos Therapeutics reported a net loss of $45.4 million for the third quarter of 2024, while highlighting progress in its clinical programs and a $35 million milestone payment from GSK.

iTeos Therapeutics reports a net loss of $7.1 million for the three months ended June 30, 2024, but also recognizes $35 million in license and collaboration revenue due to a milestone achievement.

iTeos Therapeutics reported a net loss of $38.2 million for the first quarter of 2024, with ongoing clinical development programs and a recent $120 million capital raise.

iTeos Therapeutics' 10-K filing summarizes the company's financial results for 2024 and highlights the clinical progress of its immuno-oncology programs.

iTeos Therapeutics' 2023 10-K filing details the company's financial status, clinical trial advancements, and strategic collaborations in the immuno-oncology space.

iTeos Therapeutics Chief Operating Officer Matthew Call disposed of all common stock and derivative securities following the company's merger with Concentra Biosciences.

iTeos Therapeutics CEO Michel Detheux disposed of common stock and stock options following the company's merger with Concentra Biosciences.

iTeos Therapeutics Director David K Lee disposed of all stock options as part of the company's merger with Concentra Biosciences.

iTeos Therapeutics' Chief Medical Officer, David Feltquate, disposed of 47,000 restricted stock units as part of the company's merger with Concentra Biosciences.

iTeos Therapeutics CFO Matthew Gall disposed of all his beneficial ownership in the company following its acquisition by Concentra Biosciences for $10.047 per share plus a CVR.

iTeos Therapeutics Chief Scientific Officer Yvonne McGrath reported the disposition of common stock and stock options following the company's merger with Concentra Biosciences.

iTeos Therapeutics, Inc. reported the immediate resignation of Tim Van Hauwermeiren from its Board of Directors, effective June 1, 2025, explicitly stating no disagreements with the company or its management.

iTeos Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

iTeos Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

iTeos Therapeutics, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

iTeos Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, to vote on the election of Class I directors and the ratification of its independent accounting firm.

Concentra Biosciences has successfully completed its tender offer and subsequent merger to acquire ITeos Therapeutics, making it a wholly-owned subsidiary.

iTeos Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 per share in cash plus one contingent value right.

Tang Capital Management and its affiliates have disclosed a 9.99% beneficial ownership stake in ITeos Therapeutics, Inc., transitioning from a passive 13G filing to an active 13D, indicating potential future discussions regarding strategic alternatives.

RA Capital Management, L.P. and its affiliates have significantly reduced their beneficial ownership in ITEOS THERAPEUTICS, INC. through a series of warrant exercises and open market sales, bringing their stake below the 5% threshold.

Investment firm EcoR1 Capital, LLC and its affiliates have disclosed a substantial 27.9% beneficial ownership stake in iTeos Therapeutics, Inc., acquired for investment purposes.

A group of investment entities and individuals, including MPM BioVentures and UBS Oncology Impact Fund, have sold 2,680,732 shares of ITEOS THERAPEUTICS, INC. common stock for over $20 million, resulting in their collective beneficial ownership falling below the 5% threshold.

Ridgeback Capital Investments L.P. and its affiliates have reported divesting their entire beneficial ownership in iTeos Therapeutics, Inc., now holding 0.0% of common stock.

Biotechnology Value Fund and its affiliates have fully divested their beneficial ownership in iTeos Therapeutics, Inc., holding 0% of common stock as of June 30, 2025.

Ridgeback Capital entities have reported a 5.1% beneficial ownership stake in iTeos Therapeutics, Inc., holding 1,942,959 common shares.

Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC have collectively reduced their beneficial ownership in iTeos Therapeutics, Inc. to 3.8% of outstanding common stock as of June 4, 2025.

A group of investment entities led by Biotechnology Value Fund, L.P. has disclosed an 8.1% passive beneficial ownership stake in iTeos Therapeutics, Inc. as of March 31, 2025.

Tang Capital Management, Kevin Tang, and affiliated entities have jointly reported beneficial ownership of 9.99% of ITeos Therapeutics, Inc.'s common stock.